Saturday 17 October 2026
Export HALO’s income statement to Excel — free account
Halozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 44.1%, free cash flow grew 141.2% and total debt rose 42.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
121.84
0.33
+0.27%
Follow HALO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
15.00 | 25.79 | 22.13 | 22.24 |
P/S ratio |
6.92 | 5.77 | 5.06 | 5.52 | |
P/FCF ratio |
11.62 | 12.51 | 11.44 | 11.39 | |
P/Operating CF |
48.14 | 36.82 | 42.40 | 38.10 | |
P/B ratio |
17.06 | 165.22 | 34.77 | 63.95 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.57 | 7.72 | 6.27 | 6.67 | |
EV/EBITDA |
11.46 | 19.20 | 15.27 | 15.43 | |
EV/Operating CF |
15.39 | 16.54 | 13.97 | 13.55 | |
EV/FCF |
12.72 | 16.72 | 14.17 | 13.76 | |
Quick Ratio |
1.25 | 3.30 | 2.14 | 1.99 | |
Current Ratio |
1.59 | 4.66 | 2.76 | 2.71 | |
Net Debt/EBITDA |
3.37 | (31.07) | 8.28 | 5.93 | |
Debt/Assets |
68.01% | 84.85% | 80.24% | 83.29% | |
Debt/Equity |
3.00 | 43.89 | 9.76 | 14.95 | |
Asset Turnover |
0.57 | 0.61 | 0.62 | 0.72 | |
Operating CF/Net income |
1.02 | (1.55) | 1.20 | 1.05 | |
Capex/Depreciation |
20.34 | (15.78) | (0.10) | (0.12) | |
Interest Coverage |
50.73 | (18.91) | 33.50 | 51.48 | |
Research and Development Expense of Revenue |
4.87% | 70.12% | 6.79% | 5.75% | |
Selling, General and Administrative Expense of Revenue |
13.01% | 17.05% | 15.36% | 11.85% | |
Intangible Assets out of Total Assets |
0.34 | 0.62 | 0.57 | 0.58 | |
Share Based Compensation of Revenue |
3.43% | 3.67% | 4.42% | 3.68% | |
Graham Net Nets |
(0.05) | (0.20) | (0.19) | (0.16) | |
Graham Number |
21.75 | 4.89 | 11.05 | 9.85 | |
Earnings Yield |
6.67% | 3.88% | 4.52% | 4.50% | |
Free Cash Flow Yield |
8.60% | 7.99% | 8.74% | 8.78% | |
Revenue per Share |
3.02 | 3.77 | 3.19 | 4.10 | |
Operating CF per Share |
1.52 | 1.83 | 1.52 | 2.05 | |
Capex per Share |
3.80 | (3.76) | (0.03) | (0.04) | |
Free Cash Flow per Share |
5.33 | (1.93) | 1.49 | 2.02 | |
Cash per Share |
5.99 | 1.19 | 2.70 | 1.97 | |
Shareholders Equity per Share |
4.30 | 0.41 | 1.86 | 1.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.30 | 0.41 | 1.86 | 1.22 | |
Free Cash Flow |
624.44 | (231.27) | 176.34 | 236.72 | |
Working Capital |
491.52 | 648.12 | 639.83 | 588.59 | |
Capital Expenditures |
445.84 | (450.30) | (3.74) | (4.17) | |
Net Current Asset Value |
(388.57) | (1,651.30) | (1,450.05) | (1,500.84) | |
EV/EBIT |
12.76 | 22.98 | 18.48 | 18.58 | |
Capex to Sales |
(1.26) | 1.00 | 0.01 | 0.01 | |
Price to Operating Income |
11.66 | 17.20 | 14.91 | 15.37 | |
| Other line items | |||||
Average Receivables |
315.89 | 374.86 | 381.31 | 386.08 | |
Average Payables |
13.88 | 15.57 | 17.09 | 21.15 | |
Average Inventory |
158.60 | 159.17 | 160.17 | 159.32 | |
Average Assets |
2,169.63 | 2,294.40 | 2,434.63 | 2,315.65 | |
Average Common Equity |
478.31 | 206.32 | 350.95 | 238.15 |
Columns are period end dates